Kodak strategists look at options for Health Group

Article

Kodak is exploring “strategic alternatives” for its Health Group. These include partnerships with other companies as well as the sale of its century-old radiology-based business.

Kodak is exploring "strategic alternatives" for its Health Group. These include partnerships with other companies as well as the sale of its century-old radiology-based business.

"We have discussed internally the consolidation happening in the industry and the opportunities in front of us," said Kevin J. Hobert, president of the Health Group and senior vice president of Eastman Kodak. "There are different ways to participate in that."

Hobert said Kodak's board of directors has given the green light to pursue options. The company has enlisted Goldman, Sachs as an adviser.

In early trading, Kodak stock fell $2.47 to $24.90, nearly 8% of the previous day's closing price, following disappointing quarterly results and news that the company was considering alternatives for its health unit. The stock regained about half its loss by midday.

No definitive steps have yet been taken toward any specific alternative, Hobert said. Rumors of a pending divestiture of the Health Group, whereby pieces would be split among major OEMs, "are more advanced than reality," he told DI SCAN.

"We are at the start of this process," he said. "We are looking at a range of alternatives, and we just won't be able to update until we have something more definitive."

The process could take months, said Hobert, who predicted there will be "a lot of interested parties."

Whichever route is chosen, he said taking care of Kodak customers and employees will be priorities.

"We have spent a long time in this industry building a reputation of trust," Hobert said. "It's very important to maintain that."

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.